Low prevalence of expression of p53 oncoprotein in oral carcinomas from Sri Lanka associated with betel and tobacco chewing

Pindborg, 1980, Oral Cancer and Precancer, 1 Johnson, 1991, A global view of the epidemiology of oral cancer, 3 Warnakulasuriya, 1987, Cancer in Sri Lanka with especial reference to oral cancer, 237 Gupta, 1980, Incidence rates of oral cancer and natural history of oral precancerous lesions in a 10-year follow-up study of Indian villagers, Community Dent Oral Epidemiol, 8, 283, 10.1111/j.1600-0528.1980.tb01302.x Hirayama, 1966, An epidemiological study of oral and oropharyngeal cancer in Central and South East Asia, Bull World Health Organ, 34, 41 International Agency for Research on Cancer, 1985, IARC monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, 37 CRC (Cancer Research Campaign), 1990, Oral cancer, Fact sheet, 14 Higginson, 1992, Human Cancer. Epidemiology and Environmental Causes, 333 Spandidos, 1989, Oncogenes and onco-suppressor genes: Their involvement in cancer, J Pathol, 157, 1, 10.1002/path.1711570102 Wynford-Thomas, 1991, Oncogenes and anti-oncogenes; The molecular basis of tumour behaviour, J Pathol, 165, 187, 10.1002/path.1711650302 Levine, 1992, The p53 tumour suppressor gene and product, 12, 59 Hecht, 1991, N-nitroso compounds and tobacco-induced cancers in man, IARC Sci Pub, 105, 54 Prokopczyk, 1987, 3-(Methylnitrosamino) propionitrile: occurrence in saliva of betel quid chewers, carcinogenicity, and DNA methylation in F344 rats, Cancer Res, 47, 467 Puisieux, 1991, Selective targeting of p53 gene mutational hotspots in human cancers by aetiologically defined carcinogens, Cancer Res, 51, 6185 Hollstein, 1991, p53 mutations in human cancers, Science, 253, 49, 10.1126/science.1905840 Bartek, 1991, Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies, Oncogene, 6, 1699 Porter, 1992, Widespread p53 overexpression in human malignant tumours, Am J Pathol, 140, 145 Finlay, 1989, The p53 proto-oncogene can act as a suppressor of transformation, Cell, 57, 1083, 10.1016/0092-8674(89)90045-7 Halevy, 1990, Different tumour-derived p53 mutants exhibit distinct biological activities, Science, 250, 113, 10.1126/science.2218501 Soussi, 1987, Cloning and characterization of a cDNA from Xenopus laevis coding a protein homologous to human and murine p53, Oncogene, 1, 71 Mora, 1980, An embryo protein induced by SV 40 virus transformation of mouse cells, Nature (London), 288, 722, 10.1038/288722a0 Oren, 1981, Post-translational regulation of the 54K cellular tumour antigen in normal and transformed cells, Mol Cell Biol, 1, 101, 10.1128/MCB.1.2.101 Ogden, 1992, Assessment of p53 protein expression in normal, benign and malignant oral mucosa, J Pathol, 166, 389, 10.1002/path.1711660411 Warnakulasuriya, 1992, Expression of p53 mutant nuclear phosphoprotein in oral carcinomas and potentially malignant oral lesions, J Oral Pathol Med, 21, 404, 10.1111/j.1600-0714.1992.tb01028.x UICC (Union Internationale Contre le Cancer), 1974 Anneroth, 1987, Review of the literature and a recommended system of malignancy grading in oral squamous cell carcinomas, Scand J Dent Res, 95, 229 Banks, 1986, Isolation of human-p53 specific monoclonal antibodies and their use in the studies of human p53 expression, Eur J Biochem, 159, 529, 10.1111/j.1432-1033.1986.tb09919.x Harlow, 1981, Monoclonal antibodies specific for simian virus 40 tumour antigens, J Virol, 39, 861, 10.1128/JVI.39.3.861-869.1981 Gannon, 1990, Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form, EMBO J, 9, 1595, 10.1002/j.1460-2075.1990.tb08279.x Pinhasi-Kimhi, 1986, Specific interaction between the p53 cellular tumour antigen and major heat shock proteins, Nature (London), 320, 182, 10.1038/320182a0 Harlow, 1985, Molecular cloning and in vitro expression of a cDNA clone for human cellular tumour antigen p53, Mol Cell Biol, 5, 1601, 10.1128/MCB.5.7.1601 Langdon, 1992, Expression of tumour suppressor gene p53 in oral cancer, Br J Oral Maxillofac Surg, 30, 214, 10.1016/0266-4356(92)90263-I Field, 1991, Elevated p53 expression correlates with a history of heavy smoking in squamous cell carcinoma of the head and neck, Br J Cancer, 64, 573, 10.1038/bjc.1991.352 Gusterson, 1991, Expression of p53 in premalignant and malignant squamous epithelium, Oncogene, 6, 1785 Shea, 1992, Overexpression of p53 protein in basal cell carcinomas of human skin, Am J Pathol, 141, 25 Blount, 1991, 17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma, Cancer Res, 51, 5482 Takahashi, 1990, Identification of intronic point mutations as an alternative mechanism for p53 inactivation in lung cancer, J Clin Invest, 86, 363, 10.1172/JCI114710 Thompson, 1992, p53 allele losses, mutations and expression in breast cancer and their relationship to clinico-pathological parameters, Int J Cancer, 50, 528, 10.1002/ijc.2910500405 Barnes, 1992, Abnormal expression of wild type p53 protein in normal cells of a cancer family patient, Lancet, 340, 259, 10.1016/0140-6736(92)92354-I Scheffner, 1990, The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53, Cell, 63, 1129, 10.1016/0092-8674(90)90409-8 Wynford-Thomas, 1992, p53 in tumour pathology: can we trust immunocytochemistry, J Pathol, 166, 329, 10.1002/path.1711660402